Marshall Wace
IBRX icon

Marshall Wace’s ImmunityBio IBRX Stock Holding History

Marshall Wace’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.4M Buy
387,700
+310,675
+403% +$2.35M ﹤0.01% 1568
2026
Q1 		$591K Buy
+77,025
New +$527K ﹤0.01% 2374
2025
Q4 		– Sell
-254,814
Closed -$627K – 3182
2025
Q3 		$627K Buy
+254,814
New +$656K ﹤0.01% 2142
2025
Q1 		– Sell
-240,311
Closed -$615K – 2832
2024
Q4 		$615K Buy
+240,311
New +$1M ﹤0.01% 1959
2023
Q2 		– Sell
-234,441
Closed -$427K – 2672
2023
Q1 		$427K Buy
234,441
+175,133
+295% +$545K ﹤0.01% 2166
2022
Q4 		$301K Buy
59,308
+7,718
+15% +$42.4K ﹤0.01% 2567
2022
Q3 		$256K Buy
+51,590
New +$235K ﹤0.01% 3000
2022
Q2 		– Sell
-153,282
Closed -$861K – 3620
2022
Q1 		$861K Sell
153,282
-90,237
-37% -$554K ﹤0.01% 2518
2021
Q4 		$1.48M Buy
+243,519
New +$1.83M ﹤0.01% 2240

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace's IBRX Position: Q2 2026 in Review

Marshall Wace increased its ImmunityBio (IBRX) stake by 403% in Q2 2026, buying an estimated $2.35M and bringing the position to 387,700 shares worth $3.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1568.

Marshall Wace first reported a position in IBRX in Q4 2021 and has held it in 9 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Marshall Wace held 387,700 shares of ImmunityBio worth $3.4M as of Q2 2026.
  • Marshall Wace bought 310,675 ImmunityBio shares in Q2 2026, an estimated $2.35M.
  • ImmunityBio made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1568 holding.
  • Marshall Wace first reported a position in ImmunityBio in Q4 2021 and has held it in 9 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.